Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Fletcher, Jonathan
Item TypeName
Academic Article Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
Academic Article Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
Academic Article Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Academic Article Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Academic Article STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
Academic Article KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Academic Article Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.
Academic Article Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Academic Article Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
Academic Article KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
Academic Article Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Academic Article Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL.
Academic Article Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Academic Article An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors.
Academic Article Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Academic Article Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
Academic Article Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Academic Article Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Academic Article Role of KIT and platelet-derived growth factor receptors as oncoproteins.
Academic Article Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Academic Article Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Academic Article KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.
Academic Article KIT mutations in GIST.
Academic Article Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Academic Article Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
Academic Article Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Academic Article Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Academic Article Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Academic Article Gastrointestinal stromal tumours: etiology, pathology and clinical management.
Academic Article Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Academic Article Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest?
Academic Article Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Academic Article Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Academic Article Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Academic Article Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Academic Article Biology of gastrointestinal stromal tumors.
Academic Article DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Academic Article Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.
Academic Article ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Academic Article A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Academic Article p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Academic Article The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Academic Article Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Academic Article KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
Academic Article Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Academic Article Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Academic Article CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Academic Article Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
Academic Article Platelet-Derived Growth Factor Receptor-a Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Academic Article Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Academic Article Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Academic Article Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Academic Article Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+).
Academic Article Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Academic Article LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Academic Article Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Academic Article Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Search Criteria
  • Mesylates
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.